A combination comprising 2 to 8 mg of 5-[4-[2-(N-methyl-N- (2-pyridyl)amino)-ethoxy]benzyl]thiazolidine-24-dione (rosiglitazone) or a tautomeric form thereof or a pharmaceutically acceptable salt or solvate thereof; and sub maximal amount of sulphonylurea selected from glibenclamide glipizide gliclazide tolazamide tolbutamide acetohexamide carbutamide chlorpropamide glibornuride gliquidone glisentide glisolamide glisoxepide glyclopyamide and glycylamide. Disclosed is also a medical use of the co...

PURPOSE: A combination kit containing pinitol and a drug for preventing or treating diabetes is provided to reduce side effects and to quickly treat diabetes. CONSTITUTION: A combination kit of a component for preventing or treating diabetes contains pinitol as a first ingredient and a drug of biguanide meglitinide or sulfonylurea as a second ingredient. The biguanide is metformin. The meglitinide is repaplinide or nateglinide. The sulfonylurea is carbutamide acetohexamide chlorpropamide tolbuta...

595024 Disclosed herein is a compound which is NN-dimethyl-5-(2-methyl-6-((5-methylpyrazin-2-yl)carbomoyl-4-yloxy)pyrimidine-2-carboxamide a pharmaceutical composition comprising it and a pharmaceutical composition further comprising an anti-obesity agent and an anti-diabetic agent. Wherein said anti-obesity agent is selected from the group consisting of dirlotapide mitratapide implitapide lorcaserin cetilistat PYY3-36 naltrexone oleoyl-estrone obinepitide pramlintide tesofensine leptin liraglut...

In the present invention there is disclosed a pharmaceutical combination containing 2 to 8 mg of 5-[4-/2-(N-methyl-N-(2-pyridyl)amino)ethoxy/benzyl]thiazolidine-24-dione (compound of the general formula I) or a tautomeric form and/or pharmaceutically acceptable derivative thereof and sulfonylurea wherein the sulfonylurea is represented by glibenclamide glipizide gliclazide glimepiride tolazamide or tolbutamide. There is also disclosed the use of the above-described combination in a pharmaceutica...

Pharmaceutical composition comprises 2 to 8 mg of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine- 24-dione i. a. rosiglitazone in the form of a free base or a tautomeric form thereof and/or in the form of a pharmaceutically acceptable derivative and a sulphonylurea preferably glibenclamide glipizide gliclazide glimepiride tolazamide or tolbutamide. Also disclosed is the use of 2 to 8 mg of rosiglitazone and a sulphonylurea for the manufacture of a medicament for the treatment of...

This invention provides methods of using a pharmacological combination of a biguanide agents such as metformin and one or more PTPase inhibiting agents and optionally one or more sulfonlylurea agents including glyburide glyburide glipizide glimepiride chlorpropamide tolbutamide or tolazamide for treatment in a mammal of Syndrome X type II diabetes or metabolic disorders mediated by insulin resistance or hyperglycemia. Further included in this invention is a method of modulating blood glucose lev...

This invention provides methods of using a pharmacological combination of a biguanide agents such as metformin and one or more PTPase inhibiting agents and optionally one or more sulfonlylurea agents including glyburide glyburide glipizide glimepiride chlorpropamide tolbutamide or tolazamide for treatment in a mammal of Syndrome X type II diabetes or metabolic disorders mediated by insulin resistance or hyperglycemia. Further included in this invention is a method of modulating blood glucose lev...

1. A method for the treatment of diabetes mellitus and conditions associated with diabetes mellitus in a mammal which method comprises administering an effective non-toxic and pharmaceutically acceptable amount of 2-12 mg per day of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-24-dione Compound (I) or a tautomeric form thereof and/or a pharmaceutically acceptable derivative thereof and a sub-maximal amount of a sulphonylurea(insulin secretagogue) to a mammal in need thereof. 2...

This invention provides methods of using a pharmacological combination of a biguanide agents such as metformin and one or more PTPase inhibiting agents and optionally one or more sulfonlylurea agents including glyburide glyburide glipizide glimepiride chlorpropamide tolbutamide or tolazamide for treatment in a mammal of Syndrome X type II diabetes or metabolic disorders mediated by insulin resistance or hyperglycemia. Further included in this invention is a method of modulating blood glucose lev...

1. A method for the treatment of diabetes mellitus and conditions associated with diabetes mellitus in a mammal with positive effect by glycemic control without observable unfavourable effects which method comprises administering 2 to 12 mg daily 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-24-dione (Compound I) or a pharmaceutically acceptable salt thereof and sulfonyl urea. 2. A method according to Claim 1 wherein the c is glibenclamide glipizide gliclazide glimepiride tola...